They added that the federal telemedicine policy is responsible for “undermining [Louisiana’s] laws protecting unborn human life” and causing the state “irreparable harm.” The decision, which applies to both states like Louisiana that ban abortion and states that allow the procedure, restores the FDA’s prior policy mandating that patients only obtain the drug in person from a physician. In their ruling, the judges rejected the Trump administration’s assertion that the state lacks standing, and that the court should hit pause on the case while the FDA conducts its own review of the drug. The court also rebuffed arguments by the two pharmaceutical companies that make mifepristone, Danco and GenBioPro, who argued that the court should defer to the FDA’s scientific judgment when it comes to whether and how patients can access the pills.